Foghorn Therapeutics, Inc. (FHTX)

Over the past six months, Foghorn Therapeutics' stock price has been impacted by several events. In November 2025, the company announced its third-quarter financial and corporate update, resulting in a stock increase, and also announced the resignation of its CFO. In October 2025, updates were provided on its selective ARID1B, CBP, and EP300 degrader programs. In August 2025, the second-quarter financial and corporate update led to a stock decrease. In May 2024, a registered direct offering raised approximately $110 million. Throughout November 2025, management participated in healthcare investor conferences. Overall, between November 18, 2024, and November 17, 2025, the share price declined by 37.81%.

As a clinical-stage biopharmaceutical company, Foghorn Therapeutics does not have traditional product demand seasonality. However, historical data suggests that buying Foghorn Therapeutics Inc. (FHTX) stock in June has the highest probability of a positive return, while January has the lowest probability, indicating some seasonality in stock market trends.

Foghorn Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing medicines by targeting genetically determined dependencies within the chromatin regulatory system. The company utilizes its proprietary scalable "Gene Traffic Control" platform to identify potential drug targets and is developing multiple product candidates primarily in oncology, including FHD-909 in collaboration with Eli Lilly and Company, and wholly-owned programs targeting various cancers.

Foghorn Therapeutics Inc. is headquartered in Cambridge, Massachusetts, United States, with operations and development efforts primarily focused within the United States.

In the past year, Foghorn Therapeutics has worked to enhance its visibility and reputation within the biotechnology sector through participation in healthcare conferences and presentations on its Gene Traffic Control platform. While there hasn't been specific negative news, the company's stock underperformed the US Biotechs industry and the broader US Market, and the CFO's resignation could be perceived negatively by some investors.

Foghorn Therapeutics Inc. has a diverse ownership structure, with institutional investors holding approximately 54.46% to 59.90% of the stock, insiders owning about 1.15%, and public companies and individual investors holding between 5.44% and 38.96%. Major institutional owners include Flagship Pioneering Inc., Fmr Llc, and Bvf Inc/il. Noubar Afeyan owns the most shares among individual owners, with significant stakes also held by insiders such as Cigall Kadoch and CEO Adrian H. Gottschalk.